New drug combo shows promise for rare eye cancer

NCT ID NCT01979523

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Mar 16, 2026 · Last updated Jun 15, 2026 · Updated 11 times

Summary

This study tests two drugs, trametinib and GSK2141795, in people with advanced uveal melanoma that has spread. The goal is to see if the combination works better than trametinib alone at slowing cancer growth. About 42 adults with this rare eye cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV UVEAL MELANOMA AJCC V7 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Institut Curie Paris

Paris, 75005, France
M D Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
The University of Liverpool

Liverpool, L69 3GA, United Kingdom
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

RECURRENT UVEAL MELANOMA STAGE IV UVEAL MELANOMA AJCC V7 STAGE IV UVEAL MELANOMA AJCC V7